3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Multiple Myeloma
44
Recurrence
12
Precursor Cell Lymphoblastic Leukemia-Lymphoma
10
Neoplasms, Plasma Cell
7
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
3
Lymphoma, Non-Hodgkin
3
Lymphoma, Mantle-Cell
3
Lymphoma
3
Lung Neoplasms
3
Leukemia
3
Immunoglobulin Light-chain Amyloidosis
3
Amyloidosis
3
Myelodysplastic Syndromes
2
Lymphoma, Large B-Cell, Diffuse
2
Leukemia, Myeloid, Acute
2
Carcinoma, Non-Small-Cell Lung
2
Burkitt Lymphoma
2
Waldenstrom Macroglobulinemia
1
Uterine Cervical Neoplasms
1
Smoldering Multiple Myeloma
1
Small Cell Lung Carcinoma
1
Rectal Neoplasms
1
Proteostasis Deficiencies
1
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
1
Oropharyngeal Neoplasms
1
Neoplasms
1
Melanoma
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphodepleting Chemotherapy
1
Interventions
carfilzomib
2
Dexamethasone
2
Cyclophosphamide
2
tivozanib
1
tislelizumab
1
pembrolizumab
1
neratinib
1
Nivolumab
1
Interleukin-15
1
Gemcitabine
1
Erlotinib Hydrochloride
1
Cisplatin
1
Capecitabine
1
Calcium Dobesilate
1
Bevacizumab
1
Albumin-Bound Paclitaxel
1
3-(1-benzenesulfonyl-2,3-dihydro-1H-indol-5-yl)-N-hydroxyacrylamide
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Disease
×
Calcium Dobesilate
×
Clear all
NCT01857115
2024-11-13
wCCyd
European Myeloma Network B.V.
Phase 1/2
Completed
63 enrolled